ATE454901T1 - Verfahren zur erhaltung zellimmuneantworten gegen proteinen - Google Patents

Verfahren zur erhaltung zellimmuneantworten gegen proteinen

Info

Publication number
ATE454901T1
ATE454901T1 AT00968937T AT00968937T ATE454901T1 AT E454901 T1 ATE454901 T1 AT E454901T1 AT 00968937 T AT00968937 T AT 00968937T AT 00968937 T AT00968937 T AT 00968937T AT E454901 T1 ATE454901 T1 AT E454901T1
Authority
AT
Austria
Prior art keywords
proteins
immune responses
cell immune
maintaining cell
vertebrate subject
Prior art date
Application number
AT00968937T
Other languages
English (en)
Inventor
Derek O'hagan
Manmohan Singh
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE454901T1 publication Critical patent/ATE454901T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/918—Immunological

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT00968937T 1999-10-13 2000-10-10 Verfahren zur erhaltung zellimmuneantworten gegen proteinen ATE454901T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15929899P 1999-10-13 1999-10-13
PCT/US2000/028040 WO2001026681A2 (en) 1999-10-13 2000-10-10 Method of obtaining cellular immune responses from proteins

Publications (1)

Publication Number Publication Date
ATE454901T1 true ATE454901T1 (de) 2010-01-15

Family

ID=22571953

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00968937T ATE454901T1 (de) 1999-10-13 2000-10-10 Verfahren zur erhaltung zellimmuneantworten gegen proteinen

Country Status (10)

Country Link
US (2) US6534064B1 (de)
EP (1) EP1221968B1 (de)
JP (2) JP2003511420A (de)
AT (1) ATE454901T1 (de)
AU (1) AU7877900A (de)
CA (1) CA2388676A1 (de)
DE (1) DE60043708D1 (de)
ES (1) ES2337017T3 (de)
PT (1) PT1221968E (de)
WO (1) WO2001026681A2 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141244B1 (en) * 1992-03-02 2006-11-28 Chiron Srl Helicobacter pylori proteins useful for vaccines and diagnostics
DK0909323T3 (da) * 1996-01-04 2007-05-21 Novartis Vaccines & Diagnostic Helicobacter pylori-bakterioferritin
US20040006034A1 (en) * 1998-06-05 2004-01-08 Eyal Raz Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
GB9807721D0 (en) * 1998-04-08 1998-06-10 Chiron Spa Antigen
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
CA2360347C (en) 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US6534064B1 (en) * 1999-10-13 2003-03-18 Chiron Corporation Stabilized protein particles for inducing cellular immune responses
WO2002038175A1 (en) 2000-11-07 2002-05-16 Immunovaccine Technologies Inc. Vaccines with enhanced immune response and methods for their preparation
ATE499948T1 (de) * 2001-01-12 2011-03-15 Novartis Vaccines & Diagnostic Nukleinsäure mukosale immunisierung
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
ITRM20010336A1 (it) * 2001-06-13 2002-12-13 Biostrands S R L Anticorpo umano ricombinante diretto contro la proteina non strutturale ns3 del virus dell'epatite c (hcv), acido nucleico codificante e usi
NZ530635A (en) * 2001-06-15 2007-03-30 Nordic Vaccine Technology As Therapeutical vaccination comprising an immunogen and a targeting vehicle comprising a carrier and a antigen silmilar to the first
AU2002322358B2 (en) * 2001-06-29 2009-06-18 Novartis Vaccines And Diagnostics, Inc. HCV E1E2 vaccine compositions
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US20050175629A1 (en) * 2001-08-31 2005-08-11 Giuseppe Del Giudice Helicobacter pylori vaccination
DE60234375D1 (de) * 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
KR20040111402A (ko) * 2002-03-13 2004-12-31 기린 비루 가부시키가이샤 인플루엔자 м2 단백질에 대한 인간 모노클로날 항체 및그의 제조 및 사용 방법
WO2003082316A1 (en) 2002-03-29 2003-10-09 The Regents Of The University Of California Microgel particles for the delivery of bioactive materials
JP2004099584A (ja) 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
AU2003299994A1 (en) 2002-12-27 2004-07-29 Chiron Corporation Immunogenic compositions containing phospholpid
US20040203084A1 (en) * 2003-04-10 2004-10-14 Doug Levinson Profiling conformational variants, antibody compositions and methods of using the same
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
FR2859909B1 (fr) * 2003-09-22 2007-09-07 Biomerieux Sa Procede de preparation de microparticules bioresorbables, microparticules obtenues et utilisation
EP1885186B1 (de) * 2005-06-01 2015-09-02 California Institute Of Technology Verfahren zur gezielten genabgabe über virale vektoren
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
WO2007047916A2 (en) * 2005-10-17 2007-04-26 Novartis Ag Multiclade hiv vaccines
US20070184068A1 (en) 2005-12-14 2007-08-09 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
CN101466720B (zh) 2006-06-12 2013-01-02 赛托斯生物技术公司 向rna噬菌体的病毒样颗粒内包装寡核苷酸的方法
AU2007275010B2 (en) 2006-07-21 2013-06-20 California Institute Of Technology Targeted gene delivery for dendritic cell vaccination
JP5389662B2 (ja) 2006-12-12 2014-01-15 サイトス バイオテクノロジー アーゲー 高濃度のグアニン・モノマーを含有するオリゴヌクレオチド
ES2588705T3 (es) 2007-09-27 2016-11-04 Immunovaccine Technologies Inc. Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
EP2244695A1 (de) 2007-12-07 2010-11-03 Novartis AG Zusammensetzungen zur induktion von immunantworten
CA2723918C (en) 2008-06-05 2018-01-09 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
JP5713897B2 (ja) * 2008-07-16 2015-05-07 エボニック コーポレイションＥｖｏｎｉｋ Ｃｏｒｐｏｒａｔｉｏｎ 生理活性ペプチドを含有する微粒子を調製するためのプロセス
HRP20140327T4 (hr) 2009-07-24 2017-11-03 Immune Design Corp Lentiviralni vektori pseudotipizirani sa glikoproteinom ovojnice virusa sindbis
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
IN2014CN02581A (de) 2011-10-06 2015-08-07 Immunovaccine Technologies Inc
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
JP2015512263A (ja) 2012-03-30 2015-04-27 イミューン デザイン コーポレイション Ｄｃ−ｓｉｇｎを発現する細胞に対して改善された形質導入の有効性を有するレンチウイルスベクター粒子
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
US20130302366A1 (en) 2012-05-09 2013-11-14 Christopher Marshall Conformationally Specific Viral Immunogens
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
IL308091B1 (en) 2016-09-13 2026-01-01 Allergan Inc Protein-free stabilized Clostridium toxin preparations
CN109963587A (zh) 2016-09-21 2019-07-02 艾伯塔大学理事会 丙型肝炎病毒免疫原性组合物及其使用方法
EP3810182A4 (de) 2018-06-19 2022-08-24 BioNTech US Inc. Neoantigene und ihre verwendungen

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2750045A1 (de) * 1977-11-09 1979-05-10 Behringwerke Ag Verfahren zur entfernung von detergentien aus virusantigensuspensionen
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
JPS62138500A (ja) * 1985-12-11 1987-06-22 Sumitomo Pharmaceut Co Ltd ポリペプチドの製法
JPH01500999A (ja) * 1986-10-20 1989-04-06 チロン　コーポレイション Ｈｓｖの治療的処置に用いるワクチン
JPH0751513B2 (ja) * 1988-04-28 1995-06-05 国立予防衛生研究所長 Ａ型肝炎ワクチン
CA2037151A1 (en) * 1990-03-23 1991-09-24 F. Hoffmann-La Roche Ag Plasmodium sporozoite antigen
WO1993020840A1 (en) * 1992-04-14 1993-10-28 British Bio-Technology Limited Induction of ctl responses
JPH08505625A (ja) * 1993-01-11 1996-06-18 ダナ−ファーバー キャンサー インスティチュート 細胞毒性ｔリンパ球応答の誘導
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
US5955342A (en) * 1994-08-15 1999-09-21 Connaught Laboratories Limited Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region
US5851826A (en) * 1995-07-26 1998-12-22 Children's Medical Center Corporation Helper virus-free herpesvirus vector packaging system
ZA982763B (en) * 1997-04-09 1998-10-05 Akzo Nobel Nv Vaccines
CA2288129A1 (en) 1997-05-01 1998-11-12 Chiron Corporation Use of virus-like particles as adjuvants
EP0913479A3 (de) * 1997-10-27 2000-10-25 Smithkline Beecham Corporation Adenin Glycosylase
CA2314934C (en) * 1997-12-16 2006-08-29 Chiron Corporation Use of microparticles combined with submicron oil-in-water emulsions
ES2237115T5 (es) * 1998-06-24 2008-05-16 Innogenetics N.V. Particulas de proteinas de la envoltura del hcv: uso para la vacunacion.
US6534064B1 (en) * 1999-10-13 2003-03-18 Chiron Corporation Stabilized protein particles for inducing cellular immune responses

Also Published As

Publication number Publication date
EP1221968B1 (de) 2010-01-13
US20030104067A1 (en) 2003-06-05
ES2337017T3 (es) 2010-04-20
WO2001026681A2 (en) 2001-04-19
DE60043708D1 (de) 2010-03-04
WO2001026681A3 (en) 2002-01-31
JP2003511420A (ja) 2003-03-25
JP2011116796A (ja) 2011-06-16
US7604802B2 (en) 2009-10-20
AU7877900A (en) 2001-04-23
CA2388676A1 (en) 2001-04-19
PT1221968E (pt) 2010-04-16
EP1221968A2 (de) 2002-07-17
US6534064B1 (en) 2003-03-18

Similar Documents

Publication Publication Date Title
ATE454901T1 (de) Verfahren zur erhaltung zellimmuneantworten gegen proteinen
ATA1292000A (de) Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
EP0757717A4 (de) Papillomavirus vakzine
AU2903999A (en) Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines
WO2001034801A3 (en) Recombinant gelatin in vaccines
IL132468A0 (en) A kit for inducing immune response against a tumor or a disease caused by an infection agent
BG104828A (en) Fap alpha-specific antibody with improved pruducibility
EP2325205A3 (de) Kristalle von ganzen Antikörpern und Fragmenten davon und Verfahren zu ihrer Herstellung und Verwendung
DK1054689T3 (da) Strategisk modificerede hepatitis B-kerneproteiner og derivater deraf
ATE236255T1 (de) Impfstoff gegen den hepatitis e-virus und verfahren
DE69930630D1 (de) B2microglobulin fusionsproteine und varianten mit hoher affinität
JP2003515569A5 (de)
WO2002088328A3 (en) Method for generating highly active human dendritic cells from monocytes
DE60331725D1 (de) Therapeutische mittel als antikrebs impfstoffadjuvantien und deren therapeutische verfahren
EP1801123A3 (de) Kristalle von ganzen Antikörpern und Fragmenten davon und Verfahren zu ihrer Herstellung und Verwendung
FI924746A7 (fi) Kohydrolyysimenetelmä uusien uutteiden valmistamiseksi hiiva- ja ei-hi ivaproteiineista
DE69933875D1 (de) Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
EP0957936A4 (de) Zusammensetzungen von rekombinanten papillomavirus vakzinen
ATE310750T1 (de) Verotoxin b untereinheit zur immunisierunug
AU7546500A (en) Designing immunogens
DE602004019141D1 (de) Isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonin (ivtntt) enthaltende biologisch wirksame peptide
AU1227700A (en) Method for the production of purified invasin protein and use thereof
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
AU2002221553A1 (en) Vaccines containing recombinant hantavirus proteins, methods for producing said vaccines and their use
DE59704883D1 (de) Komplex aus antigen und zellbestandteil, verfahren zur dessen herstellung und therapeutische verwendungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1221968

Country of ref document: EP